Atrium Therapeutics, Inc. filed a current report on Form 8-K on November 2, 2026, disclosing an upcoming poster presentation of new nonclinical data for its lead investigational therapy ATR-1072 at the Hypertrophic Cardiomyopathy Medical Society session at the American Heart Association Scientific Sessions 2026.

Key Highlights

  • Presentation date and location: Atrium Therapeutics will present on November 6, 2026, in Chicago, Illinois, at the HCMS session during the American Heart Association Scientific Sessions 2026.
  • Target indication: The nonclinical data support ATR-1072 for the potential treatment of PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome.
  • Mouse model: According to the filing, results were generated in a new mouse model of PRKAG2 syndrome developed by the company that demonstrates cardiac glycogen accumulation, cardiac hypertrophy, and ECG abnormalities.
  • Key finding: The filing states that treatment with mATR-1072, a mouse surrogate of ATR-1072, "led to reversal of cardiac glycogen accumulation as well as improvement in other key features of the disease, including hypertrophy and ECG parameters."
  • Dosing: According to the filing, mice received a single dose of mATR-1072 after features of the disease had been established for three weeks.
  • Corporate presentation updated: The company also disclosed that it updated its corporate presentation as of November 2, 2026, to be posted on its investor relations website.

Atrium Therapeutics Reports Nonclinical Results for ATR-1072 in PRKAG2 Syndrome Model

Atrium Therapeutics, Inc. (NASDAQ:RNA), headquartered in San Diego, California, filed a current report disclosing plans to present new nonclinical data for its lead investigational candidate ATR-1072 at the Hypertrophic Cardiomyopathy Medical Society (HCMS) session at the American Heart Association Scientific Sessions 2026, scheduled for November 6, 2026, in Chicago, Illinois. The report was filed under Items 7.01 and 8.01, covering Regulation FD disclosure and other events, respectively.

According to the filing, the nonclinical data were generated using a new mouse model of PRKAG2 syndrome developed internally by the company. The model, the filing states, demonstrates key disease features including cardiac glycogen accumulation, cardiac hypertrophy, and electrocardiogram abnormalities. In the study described, mice received a single dose of mATR-1072, described in the filing as "a mouse surrogate of ATR-1072," after disease features had been present for three weeks. The filing states that by "targeting disease causing variant PRKAG2 mRNA in the heart," treatment led to reversal of cardiac glycogen accumulation and improvement in cardiac hypertrophy and ECG parameters.

The filing also notes that the company updated its corporate presentation as of November 2, 2026, and that it would be made available on the investors section of the company's website. The filing identifies Atrium Therapeutics as an emerging growth company. The information furnished under Item 7.01, including Exhibit 99.1 (a press release dated November 2, 2026) and Exhibit 99.2 (the corporate presentation), is designated as "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as the filing states.

What Was Disclosed

Atrium Therapeutics disclosed via an 8-K filed November 2, 2026, that it will present nonclinical data for ATR-1072 in a PRKAG2 syndrome mouse model at the AHA Scientific Sessions on November 6, 2026, in Chicago, accompanied by an updated corporate presentation.